Xeris Biopharma (NASDAQ:XERS) Insider Sells 27,600 Shares of Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Steven Pieper sold 27,600 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $8.52, for a total transaction of $235,152.00. Following the completion of the sale, the insider directly owned 1,366,053 shares in the company, valued at $11,638,771.56. This represents a 1.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Pieper also recently made the following trade(s):

• On Monday, July 6th, Steven Pieper sold 17,400 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.50, for a total transaction of $147,900.00.

Xeris Biopharma Price Performance

Shares of Xeris Biopharma stock traded up $0.57 on Tuesday, hitting $8.94. 3,479,668 shares of the company traded hands, compared to its average volume of 1,914,952. The firm’s 50-day simple moving average is $6.65 and its 200 day simple moving average is $6.64. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00. The company has a market cap of $1.54 billion, a P/E ratio of 149.00 and a beta of 0.62. Xeris Biopharma Holdings, Inc. has a 12-month low of $4.66 and a 12-month high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last announced its earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. The company had revenue of $83.13 million during the quarter, compared to analyst estimates of $79.83 million. Analysts expect that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $10.80.

Institutional Trading of Xeris Biopharma

Institutional investors have recently added to or reduced their stakes in the business. Royal Bank of Canada grew its stake in shares of Xeris Biopharma by 1,411.2% during the first quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock valued at $1,170,000 after buying an additional 198,984 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Xeris Biopharma by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock valued at $461,000 after acquiring an additional 3,594 shares during the period. Millennium Management LLC boosted its holdings in Xeris Biopharma by 19.0% during the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock valued at $12,726,000 after acquiring an additional 369,420 shares during the period. Goldman Sachs Group Inc. grew its position in Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after acquiring an additional 1,199,435 shares during the last quarter. Finally, Caxton Associates LLP bought a new position in Xeris Biopharma during the 1st quarter worth approximately $170,000. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.